Avacta Share Discussion Threads

[danatkins] 28/3/2018 19:14

Escapetohome so you made a purchase today? All coming up as sells. Would be good to know thanks

[danatkins] 28/3/2018 19:00

Agreed, very strange as its been falling on very small sells. You would think that trade would have moved the needle. The only thing I can think off is an II sell. But why sell that amount now?

[escapetohome] 28/3/2018 18:51

Not sure, didnt seem to move the price at all, it seemed to go through at the very same price as my much smaller trade.

[danatkins] 28/3/2018 17:45

Buy or sell? What's your opinion

[escapetohome] 28/3/2018 16:12

215,000 share trade

[escapetohome] 28/3/2018 16:11

Ive just had a small top up, hopefully news at the PROACTIVE INVESTORS EVENT???

[aim_trader] 26/3/2018 11:07

Avacta to present to investors at the upcoming Proactive One2One Healthcare Forum on 5th April in London. For details and registration, click here:

[the drewster] 19/3/2018 12:53

It is in "punt" territory.

[ffp] 18/3/2018 22:40

I like the story and am sticking with it... What the hell it may or may not. in it to win it!!!!

[lantanatony] 18/3/2018 22:13

You may think,that I keep going about the Avacta brokers.
But let me point out once again that when they were appointed,Avacta shares were around one pound.
Furthermore,as market makers they seem happy to preside over any dramatic drop in the share price ,even on the sale of just a small amount of shares.
Yet their Analysts are still predicting a Two pound share price!
Talk about a "Toffee shop ".
No that's unfair on Toffee Shops!
Meanwhile,Avacta keep announcing hopeful information,but no meaningful revenue streams to support them.
How could anyone realistically believe that this is a company capable of clinical drug development?
Watch out for IP Group loading up Avacta with their next best idea.
Then another speculative fundraising.
Unfortunately,it's a very sad story.
The Avacta Board need to examin their Corporate responsibility.
You can not keep telling shareholders that you are going into clinical Development without a creditable structure and of course the finance.......can you?

[lantanatony] 12/3/2018 22:45

It seems to me the Avacta broker has given up on Avacta.
Pity it's not the other way around.
One thing is for sure any fund raise at this price will hurt.
Dr Smith and the rest of the Board
Should get a grip or give way.

[escapetohome] 11/3/2018 08:40

Because there may be something!!!
How about a fund raise for starters?

How much cash has this outfit got? Are they a cash generative business?
.

[lantanatony] 10/3/2018 23:04

Why,no statement from the company on the dramatic fall in the share price ?

[lantanatony] 26/2/2018 21:39

Yes.
It's a car crash!
I blame IP Group for loading them up with all their jam tomorrow stuff.
RIP.
The moral of the story is never invest in a University Company.

[poacher45] 26/2/2018 19:11

In my opinion what do you expect they have been a total failure at every thing they have tried and expenses have rocketed every year. Shareholders expect to see a profit they have never ever made a profit even though the chairman forecast a profit 7 years ago.

[the drewster] 26/2/2018 18:49

The Market simply isn't attaching ANY value to any of the recent tie ups or scientific inflection points ... will it ever? and if so how much?

Depressing chart.

[lantanatony] 23/2/2018 12:15

Who knows.
They keep going into jam tomorrow projects.

[escapetohome] 22/2/2018 21:57

How much cash have they got?

[lantanatony] 22/2/2018 21:48

If Avacta are a bargain.
Why are none of the big boys from the sector buying?
Is it thatthey don't believe the story?

[lantanatony] 16/2/2018 14:21

This is madness.
Someone sells 108 shares and it knocks 3% off the company's value.
Where is the broker support?!

[lantanatony] 15/2/2018 15:20

Simply no support from the broker!
Where is the bottom?

[lantanatony] 23/1/2018 10:45

Another small self founded deal.
But no big fish biting!

[derekj1] 31/12/2017 10:28

I agree with Dec2000's points below but manufacturing to GMP standards is a whole new ball game from making small proteins for lab use. Assuming affimers can be made to meet the regulatory requirements for human trials, then the issue becomes how they can be differentiated from alternative for immuno-oncology trials. Like most small proteins, half-life can be extended by turning them into single-chain antibody-like proteins to extend half life by reducing renal clearance. Affimers could then be modified further to make them multimers to different binding sites. You then end up with something looking similar to bispecific single chain antibody but have made the manufacturing process more complex. However, the key issue is will these therapeutic proteins demonstrate improved properties over the competition that biotechgeek refers to? For example, will they show better penetration into solid tumours? Can they "pull" T-cells deeper into the tumour. Very exciting if they can but this will require a lot of cash to prove these theoretical benefits. Certainly worth watching this technology evolve to see how it will complete with the more established players.

[derekj1] 31/12/2017 10:27

I agree with Dec2000's points below but manufacturing to GMP standards is a whole new ball game from making small proteins for lab use. Assuming affimers can be made to meet the regulatory requirements for human trials, then the issue becomes how they can be differentiated from alternative for immuno-oncology trials. Like most small proteins, half-life can be extended by turning them into single-chain antibody-like proteins to extend half life by reducing renal clearance. Affimers could then be modified further to make them multimers to different binding sites. You then end up with something looking similar to bispecific single chain antibody but have made the manufacturing process more complex. However, the key issue is will these therapeutic proteins demonstrate improved properties over the competition that biotechgeek refers to? For example, will they show better penetration into solid tumours? Can they "pull" T-cells deeper into the tumour. Very exciting if they can but this will require a lot of cash to prove these theoretical benefits. Certainly worth watching this technology evolve to see how it will complete with the more established players.